Product Description
Orally bioavailable potent MALT1 degrader compound with good PK properties and in vivo efficacy. ZE66-0205 leads to on target degradation of CBM target proteins and represents a promising new treatment strategy for DLBCL and other B-cell malignancies. (Sourced from: https://ashpublications.org/blood/article/144/Supplement%201/2783/532582/Development-of-ZE66-0205-a-Novel-MALT1-Degrader)
Mechanisms of Action: MALT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eilean
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|